Articles from AlivaMab Biologics, LLC

AlivaMab Biologics and Ablexis Congratulate Boulevard Bio on its Launch and the Ongoing Phase 1 Clinical Trial of Bispecific Antibody BLVD101
Fully human dual-antagonist bispecific antibody discovered and engineered at AlivaMab Biologics
By AlivaMab Biologics, LLC · Via ACCESS Newswire · August 13, 2026
Articles from AlivaMab Biologics, LLC | Hannibal Courier - Post